FDA Denies Petition Seeking Withdrawal of Jazz’s Lung Cancer Drug Approval

The FDA has rejected a citizen petition pressing the agency to revoke the accelerated approval for Jazz Pharmaceuticals’ and PharmaMar’s Zepzelca (lurbinectedin), a treatment for adults with metastatic small cell lung cancer (SCLC).
Source: Drug Industry Daily